Podcasts about Myasthenia

Obstructive sleep apnea affects approximately one in four adults and is especially common among patients with neurologic disorders, including stroke, Parkinson disease, dementia, epilepsy, and neuromuscular conditions. In this episode, Dr. Stephanie Stahl discusses why neurologists should routinely screen for OSA, highlights key symptoms and risk factors, reviews important considerations when interpreting sleep studies, and outlines current treatment options beyond CPAP. Learn how recognizing and treating sleep apnea can improve quality of life, optimize management of neurologic disease, and reduce long-term health risks. In this episode, Aaron L. Berkowitz, MD, PhD, FAAN, speaks with Stephanie M. Stahl, MD, FAASM, author of the article "Obstructive Sleep Apnea" in the Continuum® August 2026 Sleep Neurology issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Dr. Stahl is an Associate Professor of Clinical Medicine and Sleep Medicine Fellowship Program Director at Indiana University School of Medicine in Indianapolis, Indiana, where she also serves as Sleep Laboratory Medical Director in the Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine. Additional Resources Read the article: Obstructive Sleep Apnea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz  Full episode transcript available here Dr Berkowitz: Obstructive sleep apnea is very common. It can cause or contribute to common neurologic symptoms, such as headache and impaired cognition, and it's a risk factor for stroke. And yet, if you're like me, you may not know too much more about sleep apnea than that. Today, I have the pleasure of talking to sleep expert Dr. Stephanie Stahl to learn what every neurologist should know about OSA.  Dr Jones:  This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Berkowitz: This is Dr. Aaron Berkowitz. Today I'm interviewing Dr. Stephanie Stahl about her article on obstructive sleep apnea. This article appears in the 2026 Continuum issue on Neurology of Sleep. Welcome to the podcast, Dr. Stahl, and could you please introduce yourself to our audience?  Dr Stahl: Yeah. Thank you for having me. I'm a sleep medicine physician and neurologist and medical director of the Indianapolis Sleep Lab at Indiana University Health. I serve as the director of the Sleep Medicine Fellowship program. I'm faculty advisor for our very first student interest group in sleep medicine at Indiana University School of Medicine. I'm also actively involved in some national leadership roles, including the incoming chair of the American Academy of Sleep Medicine's Education Committee and co-chair of the Academy's Inter-Scorer Reliability Gold Standard Panel. So, I really appreciate this opportunity. I look forward to our discussion.  Dr Berkowitz: Me too, and we appreciate the opportunity too to get to talk to you. You have so much expertise in this area, and I certainly encourage our listeners to look at your article, which is very comprehensive and up to date, and I learned a ton from it. I didn't get much exposure to sleep neurology as a trainee, and I've always worked in academic centers where we have a sleep group and we can refer patients there. So, I have to admit, sleep may probably be the area of neurology I know the least about, and felt like I was learning something new from pretty much every line of your article, and I know our readers will too. So, your article has a lot of excellent detail for our readers on the diagnosis and treatment of this very common condition. But I'd like to keep our interview relatively high level today and focus on the essentials for the practicing general neurologist. So, to start, can you just give us a sense of what obstructive sleep apnea is, and what every neurologist should know about it?  Dr Stahl: Yeah. So obstructive sleep apnea is characterized by either partial or full obstructions in the upper airway. That may sound pretty simple, but this leads to a whole bunch of issues. It leads to oxygen desaturations, arousals from sleep, leading to sleep fragmentation. This can then lead to sympathetic nervous system activation, cerebral hypoperfusion, leading to a whole bunch of symptoms or neurologic conditions.  Dr Berkowitz: Great. And you mentioned this in your article, but just to emphasize, how common is obstructive sleep apnea in the general population?  Dr Stahl: Yeah. So, about a quarter of the general population have obstructive sleep apnea. Much more common in many neurologic conditions.  Dr Berkowitz: Yeah, so very common disorder. We are seeing patients with it quite frequently, whether that's the reason they are seeing us in neurology or not. And this leads to my next question, which is what neurologic symptoms or presenting concerns of a patient should make us think about OSA and the differential diagnosis, and what factors based on the history or the exam or the context would make you suspicious for OSA as the cause of a neurologic symptom? In other words, the patient's presenting with classic symptoms of OSA, and that's why they're seeing a neurologist or seeing a primary care doctor, but is coming for evaluation of, say, headache or other symptoms. And what symptoms would make you think of wanting to consider OSA, and then what aspects of the history or otherwise would make you want to evaluate the patient for OSA?  Dr Stahl: I think a really important takeaway is for neurologists to know that obstructive sleep apnea is very common in neurologic conditions and has that potential to worsen a lot of these conditions or their associated symptoms. And so, it should be on our radar. There are certainly some basic questions and signs and symptoms that we can ask patients about or, or take a look at on exam. And so particular symptoms include snoring. Anybody that snores loudly or frequently, that's a strong risk factor for obstructive sleep apnea. If someone's seeing them stop breathing in their sleep, if they are waking up a lot throughout the night. There are some other symptoms that we may not necessarily attribute upfront to obstructive sleep apnea, such as nocturia, nocturnal reflux, night sweats. There are some daytime symptoms, of course, too, like unrefreshing sleep, daytime sleepiness, morning headaches, an important one in neurology. And then we take a look at the patient's exam. And so, some things that neurologists might want to be thinking about are people with obesity are certainly at a risk for obstructive sleep apnea. But it's also very important to know that someone does not need to have obesity in order to have obstructive sleep apnea. We look at neck size, other morphologic characteristics, such as how much that we can see in the back of their mouth. Can we see their uvula? Does their tongue size appear large in their mouth? And then some other risk factors too, such as male gender, older age, family history, post-menopausal state in women. All that being said, though, sometimes in neurologic conditions, we don't have all of those symptoms or risk factors to be thinking about. And so, in certain neurologic conditions such as stroke where obstructive sleep apnea is very common and has the potential to increase the risk of another stroke, we may need to be thinking about testing these patients even with minimal symptoms or other risk factors.  Dr Berkowitz: That's very helpful. So, you mentioned their headache might be the presenting symptom, right, to a neurologist, and we should certainly be thinking about obstructive sleep apnea as a potential diagnosis, even the cause of the patient's headache, particularly you said patients with morning headache. I often try to think about in patients presenting with, for memory loss, or other cognitive concerns, and that may be due more to inattention from poor sleep, so asking about sleep and symptoms of sleep apnea in those contexts. Are there any other presenting neurologic symptoms not particularly related to sleep? I'm thinking of headache, memory loss, other symptoms that would make you think, "Oh, I should actually screen this patient for sleep apnea also."  Dr Stahl: Yeah, other symptoms to think about in pediatrics, hyperactivity, people that have impaired vigilance, as you alluded to, that poor attention. Sometimes people get misdiagnosed with ADHD, and it's actually just a manifestation of obstructive sleep apnea.  Dr Berkowitz: You alluded to this, Dr. Stahl, that stroke, for example, patients are at higher risk of developing sleep apnea as a result of stroke, and it's also a risk factor for stroke. What other neurologic conditions, primary neurologic diseases, put patients at a higher risk of OSA? And again, similar to the last question I asked you, what are some clues that we should evaluate for? We might be following a patient for their post-stroke care over time and not necessarily thinking about diagnosing a separate condition in them since we're following them for their stroke or their degenerative disease. What are the conditions that put patients at a higher risk of OSA as a result of the condition, and then when would you think about screening them for it?  Dr Stahl: Some particular neurologic conditions where obstructive sleep apnea are very common, in addition to stroke and, and TIA, include Parkinson disease. It can worsen a lot of the motor, cognitive symptoms, sleep disruption that we can see in Parkinson disease. Very common in all causes of dementia, but in particular Alzheimer disease and Lewy body dementia. Very common in neuromuscular conditions. We should definitely have obstructive sleep apnea and all forms of sleep-disordered breathing high on our radar. In conditions like myotonic dystrophy. Charcot-Marie-Tooth is another one where obstructive sleep apnea is very common. Myasthenia gravis, it can worsen the symptoms of that. In particular, a pearl is if somebody has morning weakness in myasthenia gravis, obstructive sleep apnea should be high on your radar. And also, as you mentioned, any forms of headaches. There are some other things too. If somebody has poor seizure control, especially nocturnal seizures, you might have obstructive sleep apnea on your radar as well.  Dr Berkowitz: So, I think you've covered essentially every category of neurologic disease, right? We have cerebrovascular, movement, neurodegenerative, neuromuscular, epilepsy, all conditions where either the disorder itself, such as stroke or the, correct me if I'm wrong, the neurodegenerative disease puts the patient at risk. Or the patient may be at risk for exacerbations of their disease, as you mentioned in myasthenia. I love that pearl. Not fatiguable at the end of the day, but if the patient with myasthenia is telling you they're feeling weaker at the beginning of the day, then think about obstructive sleep apnea and that obstructive sleep apnea worsening control of epilepsy due to poor sleep. So really a lot of bidirectional interactions with this common condition. Okay, so if we're concerned about obstructive sleep apnea, again, myself, a general neurologist speaking perhaps on behalf of other general neurologists, we see a patient with headache or reporting memory loss that we find to be impaired attention, or we see exacerbation of their underlying primary neurologic disease. As you mentioned, we think, "Oh, I've listened to this podcast. I've read Dr. Stahl's article. I should probably be thinking about OSA in this patient, and I should order a sleep study." Now, I admit when I get the sleep study back, I scroll to the bottom, I see they do have obstructive sleep apnea, I'm going to send them over to a sleep specialist. But for the general neurologist, what are some high-yield pearls and some pitfalls to be aware of when we get sleep studies for obstructive sleep apnea, and we are looking at the results? Dr Stahl: The first thing is to understand that there are two main types of sleep studies: in-lab polysomnography and home sleep apnea test. In-lab studies are typically what we consider the more accurate type of study. Main reason for that is that we have EEG, so we can see if someone is awake versus asleep. Most home sleep apnea tests do not utilize EEG, and so when we're looking at respiratory events, apneas or hypopneas, we're looking at over the total recording time rather than the total sleep time. So, we know we're going to capture some time where a person is awake, where we don't have sleep apnea events, and that can be a big amount of time in people with insomnia, poor sleep efficiency. And as a result of that, it can lead to an underestimation of the apnea-hypopnea index. That's really important for people to understand that that means we can end up with a false negative home sleep apnea test, or it can put them in a category of lower severity than what they actually have. And so, if you get a home sleep study report back that's negative for sleep apnea and you remain concerned, you need to go on to do an in-lab study, where about twenty to fifty percent of people will go on to have a positive in-lab study. You can also get false positives with home sleep apnea tests too, and so ideally, we should only be doing home sleep apnea tests in people that are at high risk of having obstructive sleep apnea to decrease our chance of false positive study. When we get that sleep study report, what's important to take a look at? So the main number that we look at currently is the apnea-hypopnea index. The number of apneas, which are full obstructions in that upper airway, or hypopneas, partial obstructions in the upper airway where either there's an oxygen desaturation or an arousal associated with that. Less than five is considered to be normal. Anything five or more gives them a diagnosis of obstructive sleep apnea, and then we stratify them based on the AHI. But it's important to take a look at more than just the apnea-hypopnea index. And while my eyes too on various reports like echocardiograms want to jump to the impression, it is important to take a look at that full report, see what their oxygen levels averaged and what they dipped down to. The arousal index, which is how many times a patient may have woken up briefly throughout the night. Take a look at the histogram, usually an image at the bottom of their report that shows what sleep fragmentation may have been like so that you can take that all in and make that decision. How important are these study findings, and is this a person that would benefit from treatment?  Dr Berkowitz: That's a fantastic overview of sleep studies and some of the highlights to look out for, even if we won't be understanding every detail as you would to know most importantly the caveats about home sleep testing having a fairly high percentage of false negative and false positive results. So being wary if our suspicion is high, and that test is normal or inconclusive to get an in-lab sleep study. And if our suspicion is low or maybe we haven't ordered the test and the patient has had it done elsewhere, and the history doesn't really match up to know that there are false positives on the home studies as well, and again, an in-lab study to settle the diagnosis. Is that right?  Dr Stahl: Yes.  Dr Berkowitz: Okay. Now, for most neurologists, probably if we diagnose OSA, we will be referring the patient to a sleep specialist like yourself for treatment. I think we're all familiar with CPAP and patients being on CPAP. Your article mentions a number of treatment modalities I admit I have not heard of before or maybe heard of in passing, acknowledging most general neurologists are not going to be prescribing or knowing with the nuance that you do as an expert how to decide which treatment a patient would most benefit from or most qualify for. So, can you just give us a broad overview, again, for the general neurologist acknowledging we might see a patient whose past medical history says OSA being treated with fill in the blank. What are the different treatment modalities, and how do you think, just so we can learn from you in broad brush strokes, about particular treatments for particular patients?  Dr Stahl: As you mentioned, most people are familiar with positive airway pressure or PAP therapy, and that does remain our most efficacious treatment. The way I explain it to patients is why PAP therapy is the most effective treatment is it's the only treatment that can take all of the tissues of that upper airway and open them up. Whereas all of our other treatments, we're going to target smaller spaces of that upper airway. So, our first option is if we can get somebody on PAP therapy, we know that that's going to be the best option for the majority. PAP therapy works by basically acting as an air splint to open up the air tissues. Know that masks are not interchangeable. There are masks that cover the nose and go over the nose and mouth and under the nose. Full face masks that cover the nose and mouth, they do typically require higher pressures, also tend to be less comfortable for a lot of patients as well. In addition to different PAP masks, there's different modalities of positive airway pressure therapy too. There are machines that auto-adjust, some that provide fixed pressure, bi-level PAP that provides a higher inspiratory pressure, lower expiratory pressure. Then outside of PAP therapy, there are, as you alluded to, a lot of options and more, continuing to come down the pipeline as well. Mandibular advancement devices or a form of oral appliances has been around for a while. This is device that somebody wears in their mouth. It's preferably customized for their teeth and titratable, meaning that they can make adjustments that pulls their mandible forward in relation to the maxilla in order to pull those tongue tissues further away from the back of the upper airway. That's ideally managed by a qualified sleep dentist or someone that specializes in oral appliance management. Other treatments include surgical options, including hypoglossal nerve stimulation, which is an implanted device that causes the tongue to protrude repetitively throughout their sleep period to hopefully open up the airspace. There's some other surgical options too that open up various places of the upper airway. There's a daytime treatment of obstructive sleep apnea, transoral neuromuscular electrical stimulation that changes the muscle fiber type of the tongue. And then there's some adjunctive treatments that can be helpful too, such as positional therapy, oral facial myofunctional therapy that helps a person breathe better through their nose and may help train the upper airway muscles.  Dr Berkowitz: Great. Well, that's a very helpful overview, and again, I refer our listeners to your article, which talks about all of those modalities in very comprehensive detail. So, Dr. Stahl, as we wrap up our conversation, you have a captive audience of neurologists and neurology trainees here. What would you like to leave us with that every neurologist should know about obstructive sleep apnea?  Dr Stahl: The most important, again, is for neurologists to know that obstructive sleep apnea is so common in your patient population, and it can have a significant negative impact on quality of life and health, including many neurologic conditions. And at the same time, obstructive sleep apnea is very treatable. We have so many options nowadays that we can usually get someone onto adequate treatment. And treatment has that potential to improve several neurologic symptoms and disorders, even at times when you don't think that there's an opportunity to improve symptoms such as say in, headache. So, neurologists really should be screening for signs and symptoms of obstructive sleep apnea, as well as considering testing in high-risk, potentially asymptomatic or minimally symptomatic patients.  Dr Berkowitz: That's a fantastic overview of some of the many pearls that you shared with us today, as well as in your article. So, thank you so much again. Today, I've been interviewing Dr. Stephanie Stahl about her article on obstructive sleep apnea. This article appears in the August 2026 Continuum issue on neurology of sleep. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining today, and thank you again, Dr. Stahl.  Dr Stahl: Thank you again for having me.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.  

The latest highlights from the journal are set to give confidence when trying something new. In this podcast for the June 2026 issue of Practical Neurology, co-editors Phil Smith and Geraint Fuller bring a distillation of the wisdom found in the journal's pages. They explain the crucial role of a Zeitgeber for healthy sleep cycles, question the involvement of drugs like SSRIs in seizures, and share a transatlantic follow-up to the ABN myasthenia gravis guidelines which provides an approach to optimising over all patient well-being.  There's also a guide to recent treatment of Parkinson's using foslevodopa-foscarbidopa infusion, also known as Produodopa. Then the editors explore the structure of the retina while touching on optic neuritis, and finish with limb-shaking transient ischaemic attacks, an early warning signal for stroke. Listen to the very end for some editorial insight into practical uses for the podcast itself! Read the issue: https://pn.bmj.com/content/26/3/205 Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol. Production and editing by Brian O'Toole. Thank you for listening. 

In episode 99 of the Medical Nursing Podcast, join Zoe Hatfield (RVN, VTS in Neurology) and Laura Jones (RVN, VTS in Internal Medicine) as they discuss one of the most common neurological disorders seen in practice: Myasthenia gravis, or MG. MG is a disorder of the neuromuscular junction causing significant weakness, megaoesophagus, regurgitation, aspiration and recumbency - and these patients need INTENSIVE nursing care to recover.  We're breaking down exactly what MG is, how it impacts our patients, and the skills we can use when caring for them, in this episode. --- About Zoe: Zoe qualified as a registered veterinary nurse in 2012. After spending her first year as a RVN working in first opinion practice, she moved to referral joining the University of Glasgow Small Animal Hospital nursing team in 2013.  Since joining the nursing team, Zoe has developed her passion for neurology and in 2019 gained the VTS certificate in Neurology.  Working within the vet school she enjoys using her extensive experience in neurology to teach and educate students and newer members of staff.  She also presents CPD on a wide variety of neurological topics, including at BSAVA Alba, ExcelCPD, VetTrust, AIMVT and BVA Live. Watch Zoe's excelCPD webinar series here. --- More free ways to learn with me:

Myasthenia gravis is een auto-immuunziekte van de neuromusculaire overgang, gekenmerkt door zwakte in specifieke spiergroepen die typisch fluctueert met inspanning en rust. Hoewel het klassieke beeld vaak goed te herkennen is, maken atypische presentaties de diagnose soms lastig. In deze aflevering spreken we met Martijn Tannemaat, neuroloog en klinisch neurofysioloog in het LUMC.  Hij neemt ons mee in de wereld van de myasthene syndromen, met de focus op myasthenia gravis, en hun onderliggende pathofysiologie. Hoe ontstaat autoreactiviteit? Wat is het typische klinische beeld, en welke diagnostiek kun je direct in de spreekkamer inzetten? En hoe onderscheid je dubbelzien door een myastheen syndroom van andere oorzaken?We bespreken de rol van aanvullende diagnostiek, waarin we ingaan op de verschillende (zeldzame) antistoffen, en ook de meerwaarde van klinisch neurofysiologisch onderzoek zoals repetitieve zenuwstimulatie en het single fiber EMG.Verder bespreken we de behandeling van myasthenia gravis, en dan met name de chronische behandeling. Wat heb je aan pyridostigmine? Wanneer moet je immuunmodulerende therapie inzetten? De behandeling van een myasthene crisis komt in een aparte aflevering van Hersenspinsels aan bod.Verder vertelt Martijn over zijn voorliefde voor de KNF en artificial intelligence. Ook doet hij een boekje open over zijn vroegere ambities om neurochirurg te worden, en zijn avontuur tijdens deelname aan het televisieprogramma Peking Express. Zie ook de Richtlijn Myasthenia Gravis versie 2.0 voor de meest recente aanbevelingen:https://www.spierziektencentrum.nl/guideline/myasthenia-gravis-autoimmuun-consensus-richtlijn/Disclosures: M.R. Tannemaat is betaald voor advieswerkzaamheden voor ArgenX, UCB Pharma, Johnson and Johnson, Peervoice en Medtalks, en heeft onderzoeksfinanciering ontvangen van ZonMW, NWO, ArgenX, USB Pharma, NMD Pharma en Huma.  Alle vergoedingen zijn betaald aan het Leids Universitair Medisch Centrum. Hij is lid van het European Reference Network for Rare Neuromuscular Diseases [ERN EURO-NMD].

In part two of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss how to approach the management of patients in clinic when there is concern for a possible false positive on the radioimmunoprecipitation assay for the acetylcholine receptor antibody. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss the clinical scenarios where the commonly used assay for myasthenia gravis is most likely to produce false positive results in patients who do not actually have myasthenia gravis. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498  

Dr. Stacey Clardy talks with Dr. Elia Sechi about the importance of understanding lab test results, the performance characteristics of assays, and the real-world implications of false positives in myasthenia gravis testing. Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Themes: Mind-Body Healing, Naturopathic Medicine, Spontaneous Healing Episode: At what point do you stop symptom tracking and stop seeking a diagnosis and really start to focus on mind-body healing? In today's episode, Dr. Moshe Daniel Block, ND, VDP, HMC, VNMI, a naturopathic doctor, author, and innovator who overcame his own diagnosis of Myasthenia gravis is here to share his expertise on mind-body healing. He created and teaches the Vis Dialogue, a transformative mind-body healing technique that has helped thousands achieve life-changing results, and offers a full certification program in Holistic Counseling. Listen to today's episode to learn how you can stop symptom tracking and start healing. Show Notes: - Dr. Moshe's experience with Myasthenia gravis and how it led to his mind-body healing work - What led to Dr. Moshe's decision to try mind-body healing instead of traditional medicine - Chi: what it is and how it feels - Dr. Moshe's experience with spontaneous healing - When to stop seeking a diagnosis and focus on the mind-body - A diagnosis vs. a prognosis  - A walkthrough of how Dr. Moshe would work with someone on mind-body healing Resources: - Visit Dr. Moshe's Website to book a consult - Enroll in Vis Dialogue Training - Lindsay's Instagram: @myvitalside or TikTok: @myvitalside - Visit Lindsay's Website - Click here for Lindsay's FREE Brain Retraining Guide   

A 70-year-old client fills in an online intake form, saying she has myasthenia gravis, hypertension, and hypothyroidism. She only takes Synthroid, and says her hypothyroidism and hypertension are well controlled. She has low back pain and muscle soreness. At first glance, this seems fairly simple. MG does not appear to be a major factor for her, because she is not controlling it with medication. But a closer look reveals some possible tangles between MG, hypothyroidism, and some cautions about hypertension drugs. Join me as I completely overthink this situation, it will be fun!   Resources:   Barnes, S. (2023) Massage is not just a luxury for those of us with myasthenia gravis | Myasthenia Gravis News. Available at: https://myastheniagravisnews.com/columns/massage-is-not-just-luxury-those-us-with-myasthenia-gravis/ (Accessed: 16 April 2025).   Myasthenia Gravis (no date a) Physiopedia. Available at: https://www.physio-pedia.com/Myasthenia_Gravis (Accessed: 16 April 2025).   Myasthenia Gravis (no date b). National Library of Medicine. Available at: https://medlineplus.gov/myastheniagravis.html (Accessed: 16 April 2025).   Myasthenia Gravis | National Institute of Neurological Disorders and Stroke (no date). Available at: https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis (Accessed: 16 April 2025).   Myasthenia gravis - causes, symptoms, treatment, pathology (2016). Available at: https://www.youtube.com/watch?v=bYGxGdu9MsQ (Accessed: 16 April 2025).   ‘Myasthenia Gravis: Practice Essentials, Background, Anatomy' (2024). Available at: https://emedicine.medscape.com/article/1171206-overview (Accessed: 16 April 2025).   Myasthenia Gravis: What Is It? (no date) Cleveland Clinic. Available at: https://my.clevelandclinic.org/health/diseases/17252-myasthenia-gravis-mg (Accessed: 16 April 2025).   Sheikh, S. et al. (2021) ‘Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update', Journal of Clinical Medicine, 10(7), p. 1537. Available at: https://doi.org/10.3390/jcm10071537.     Host Bio:                    Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.      About our Sponsors:   Anatomy Trains: www.anatomytrains.com    American Massage Conference: www.massagetherapymedia/conferences   Earthlite: www.earthlite.com   Anatomy Trains is a global leader in online anatomy education and also provides in-classroom certification programs for structural integration in the US, Canada, Australia, Europe, Japan, and China, as well as fresh-tissue cadaver dissection labs and weekend courses. The work of Anatomy Trains originated with founder Tom Myers, who mapped the human body into 13 myofascial meridians in his original book, currently in its fourth edition and translated into 12 languages. The principles of Anatomy Trains are used by osteopaths, physical therapists, bodyworkers, massage therapists, personal trainers, yoga, Pilates, Gyrotonics, and other body-minded manual therapists and movement professionals. Anatomy Trains inspires these practitioners to work with holistic anatomy in treating system-wide patterns to provide improved client outcomes in terms of structure and function.                      Website: anatomytrains.com                        Email: info@anatomytrains.com             Facebook: facebook.com/AnatomyTrains                       Instagram: www.instagram.com/anatomytrainsofficial   YouTube: https://www.youtube.com/channel/UC2g6TOEFrX4b-CigknssKHA      American Massage Conference Get ready to immerse yourself in the excitement as the American Massage Conference (AMC) arrives to Disney Springs near Orlando, Florida (May 16th-18th, 2025)! With a legacy of 17 successful years in Ontario, Canada, this premier event, proudly hosted by ONE Concept Conferences and expertly produced by Massage Therapy Media (MTM), boasts a lineup of presenters from across the nation and around the globe. The American Massage Conference began in Atlanta in 2011 and has been hosted through the years in San Diego, Chicago, and Virginia Beach. The conference provides educational opportunities with engaging one-, two-, three- and four-hour class formats, networking opportunities, masterminds, MTM Talks, demonstrations, and an extensive exhibitor tradeshow.   Mark your calendars for an unforgettable experience filled with education, networking, and the celebration of massage therapy excellence! ABMP members receive a special discount to attend this in-person conference—log in to your ABMP account to access the discount code and register today. Website: https://www.massagetherapymedia.com/conferences   Earthlite Unlock an exclusive 20 percent discount on all Earthlite products, from portable tables and chairs to professional sheets and oils. Visit earthlite.com, create an account, and enter your ABMP member ID during registration. Plus, enjoy free ground shipping on orders over $75 and a flat rate of $395 for stationary or electric lift tables. (Prices subject to change at any time.) Significant savings on everything you need to enhance your practice. We are proud to assist you as the “World's No. 1 Brand in Massage!”   Sign-up page: https://www.earthlite.com/customer/account/login/referer/aHR0cHM6Ly93d3cuZWFydGhsaXRlLmNvbS8~/  

Dr. Gordon Smith talks with Dr. Jennifer Morganroth about the increase in thymectomy procedures following the MGTX trial, the differences in access to these surgeries among various demographic groups, and the growing role of minimally invasive surgical techniques. Read the related article in Neurology® Clinical Practice. Disclosures can be found at Neurology.org.

In this episode we will discuss Myasthenia Gravis, an Autoimmune Disease affecting the neuromuscular system of the body with Tasha White, Director of a new Non-profit organization called My Walk with MG located in St. Louis, MO. ​ Myasthenia gravis is a chronic neuromuscular disease that causes weakness in the voluntary muscles. Voluntary muscles include muscles that connect to a person's bones, muscles in the face, throat, and diaphragm. They contract to move the arms and legs and are essential for breathing, swallowing and facial movements. Myasthenia gravis is an autoimmune disease, which means that the body's defense system mistakenly attacks healthy cells or proteins needed for normal functioning. The onset of the disorder may be sudden. Symptoms may not be immediately recognized as myasthenia gravis. The degree of muscle weakness involved varies greatly among individuals.    

Jointly Provided by American Academy of CME Inc and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through an educational grant from argenx US Inc.and UCB.Estimated time to complete: 0.25 hoursStart date: November 7, 2024End date: November 6, 2025This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, explains the role of  neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG).To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-pathophysiology/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the role of FcRn in MG.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection.Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

The immune system is a recurring feature in the cases discussed in this edition of the Case Reports podcast. The first paper details the cases of two young women, sisters, presenting with overlapping conditions but resulting in tragically different outcomes (1:16). Both were in their twenties, had given birth recently, and developed limb weakness along with several other neurological symptoms. https://pn.bmj.com/content/24/5/422 Our second case is a 72-yo woman with a range of symptoms including diplopia, ptosis, myalgia, and worsening shortness of breath (21:27). She had had surgical resection of a malignant melanoma, and was receiving immunotherapy treatment. Her presentation resembled myasthenia gravis, but initial treatment did not yield a response. https://pn.bmj.com/content/24/5/428  The case reports discussion is hosted by Prof. Martin Turner¹, who is joined by Dr. Ruth Wood² and Dr. Xin You Tai³ for a group examination of the features of each presentation, followed by a step-by-step walkthrough of how the diagnosis was made. These case reports and many others can be found in the June 2024 issue of the journal. (1) Professor of Clinical Neurology and Neuroscience at the Nuffield Department of Clinical Neurosciences, University of Oxford, and Consultant Neurologist at John Radcliffe Hospital. (2) Neurology Registrar, University Hospitals Sussex. (3) Clinical Academic Fellow, Nuffield Department of Clinical Neurosciences, Oxford University, and Neurology Specialty registrar, Oxford University Hospital.  Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol. This episode was produced and edited by Brian O'Toole. Thank you for listening. 

*Trigger Warning* Dyma rhybudd y bydd trafodaethau am bynciau dwys megis hunanladdiad yn y bennod yma. Hwre, mae pennod arall Cymraeg allan! Heddiw ges i'r fraint o glywed stori Erin, a dod i nabod ei phersbectif anhygoel o fyw. Dwi'n credu bod gennym ni i gyd rhywbeth i'w ddysgu o'r bennod yma, a gobeithio wnewch chi fwynhau!

Myasthenia gravis je neurologické onemocnění, které postihuje autoimunitní systém pacienta. Nejčastěji mladší ženy a starší muže. Jak se nemoc projevuje a léčí, přiblíží doktorka Jana Junkerová z Myastenického centra Neurologické kliniky Fakultní nemocnice Ostrava.Všechny díly podcastu Lékárna můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Myasthenia gravis je neurologické onemocnění, které postihuje autoimunitní systém pacienta. Nejčastěji mladší ženy a starší muže. Jak se nemoc projevuje a léčí, přiblíží doktorka Jana Junkerová z Myastenického centra Neurologické kliniky Fakultní nemocnice Ostrava.

June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles. It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and men aged 50 and older. To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion.01:07-04:26: Background on Dr Dana Vigier04:26-07:07: What is myasthenia gravis?07:07-09:43: What is the prognosis for someone diagnosed with myasthenia gravis?09:43-11:33: How effective are current treatments for myasthenia gravis?11:33-12:56: Do all the myasthenia gravis drugs work in the same way?  12:56-18:35: What R&D is taking place in myasthenia gravis?18:35-21:14: Alexion and its work on myasthenia gravis21:14-22:01: Myasthenia gravis clinical trials22:01-23:58: The importance of myasthenia gravis awareness month23:58-25:31: Would early diagnosis make a difference?25:31-27:54: Transformation through new treatmentsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

This episode sees Vicky talking all things Myasthenia with Dr Viraj Bharambe a Neurologist from Liverpool.

In unserem finalen Podcast sprechen wir mit Prof. Dr. Andreas Meisel über das Lambert-Eaton Myasthenes Syndrom (LEMS). Wo genau liegen die Unterschiede zur Myasthenia gravis und gibt es auch andere Behandlungswege? Wie kommen Betroffene mit Ihrer Krankheit klar und wie sehen die Chancen in der Forschung aus? Für Hinweise und Anregungen, Fragen und Themenwünsche wendet euch an uns unter podcast@dmg.online Homepage: https://dmg.online/ Veranstaltungen: https://dmg.online/veranstaltungen/ Publikationen: https://dmg.online/publikationen/ Social Media: https://dmg.online/social-media/ Jeden 1. Freitag im Monat sprechen wir mit Expert*innen und gehen neuen Forschungsergebnissen auf den Grund. Gleichzeitig lassen wir Betroffene zu Wort kommen, um ihre Erfolge, Fragen, Hindernisse und Erlebnisse zu hören, und auf die eine oder andere Frage eine Antwort zu suchen und eventuell zu finden. Moderiert wird er von Kulturjournalistin Amy Zayed, die selbst seit 10 Jahren mit Myasthenia gravis lebt. Vorstellung Amy Zayed: Mein Name ist Amy Zayed. Seit 2011 lebe ich mit Myasthenia gravis. Allerdings bekamen die fiesen Symptome erst 2018 endlich einen Namen. Genau deshalb ist es mir wichtig, den Menschen zuzuhören, die Rat brauchen, so wie ich ihn damals gesucht habe. Im richtigen Leben bin ich Hörfunkjournalistin für alle öffentlich-rechtlichen Jungend- und Kulturwellen sowie der britischen BBC. Seit 2020 moderiere ich den John Sinclair Podcast für den Kölner Verlag Bastei Lübbe.

In dieser folge sprechen wir mit Prof. Dr. Tobias Ruck aus Düsseldorf über Komorbiditäten. Wenn man diesen Ausdruck erstmals hört, muss man wahrscheinlich erst mal nachfragen, was zum Henker das überhaupt heiße soll! Kurzgesagt und auf Deutsch: Eine Autoimmunerkrankung kommt selten allein! Für Hinweise und Anregungen, Fragen und Themenwünsche wendet euch an uns unter podcast@dmg.online Homepage: https://dmg.online/ Veranstaltungen: https://dmg.online/veranstaltungen/ Publikationen: https://dmg.online/publikationen/ Social Media: https://dmg.online/social-media/ Jeden 1. Freitag im Monat sprechen wir mit Expert*innen und gehen neuen Forschungsergebnissen auf den Grund. Gleichzeitig lassen wir Betroffene zu Wort kommen, um ihre Erfolge, Fragen, Hindernisse und Erlebnisse zu hören, und auf die eine oder andere Frage eine Antwort zu suchen und eventuell zu finden. Moderiert wird er von Kulturjournalistin Amy Zayed, die selbst seit 10 Jahren mit Myasthenia gravis lebt. Vorstellung Amy Zayed: Mein Name ist Amy Zayed. Seit 2011 lebe ich mit Myasthenia gravis. Allerdings bekamen die fiesen Symptome erst 2018 endlich einen Namen. Genau deshalb ist es mir wichtig, den Menschen zuzuhören, die Rat brauchen, so wie ich ihn damals gesucht habe. Im richtigen Leben bin ich Hörfunkjournalistin für alle öffentlich-rechtlichen Jungend- und Kulturwellen sowie der britischen BBC. Seit 2020 moderiere ich den John Sinclair Podcast für den Kölner Verlag Bastei Lübbe.

An expert panel rank the 30 best diets for 2024; Counterfeit Ozempic on the rise; Myasthenia gravis drug approved; Herpes tests may produce false positives; Safety concerns over IV promethazine hydrochloride. 

In dieser Doppelfolge sprechen wir mit Dr. med. Adela Della Marine vom Universitätsklinikum Essen über Kinder mit Myasthenie und die Herausforderung in derer Behandlung. Direkt im Anschluss geht es weiter mit Prof. Dr. med. Heidrun Krämer-Best vom Universitätsklinikum Gießen und Marburg zum Thema Immuntherapien. Für Hinweise und Anregungen, Fragen und Themenwünsche wendet euch an uns unter podcast@dmg.online Homepage: https://dmg.online/ Veranstaltungen: https://dmg.online/veranstaltungen/ Publikationen: https://dmg.online/publikationen/ Social Media: https://dmg.online/social-media/ Jeden 1. Freitag im Monat sprechen wir mit Expert*innen und gehen neuen Forschungsergebnissen auf den Grund. Gleichzeitig lassen wir Betroffene zu Wort kommen, um ihre Erfolge, Fragen, Hindernisse und Erlebnisse zu hören, und auf die eine oder andere Frage eine Antwort zu suchen und eventuell zu finden. Moderiert wird er von Kulturjournalistin Amy Zayed, die selbst seit 10 Jahren mit Myasthenia gravis lebt. Vorstellung Amy Zayed: Mein Name ist Amy Zayed. Seit 2011 lebe ich mit Myasthenia gravis. Allerdings bekamen die fiesen Symptome erst 2018 endlich einen Namen. Genau deshalb ist es mir wichtig, den Menschen zuzuhören, die Rat brauchen, so wie ich ihn damals gesucht habe. Im richtigen Leben bin ich Hörfunkjournalistin für alle öffentlich-rechtlichen Jungend- und Kulturwellen sowie der britischen BBC. Seit 2020 moderiere ich den John Sinclair Podcast für den Kölner Verlag Bastei Lübbe.

This 15-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-pathophysiology/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 45-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Thanks Dr Megan for a great exam performance!For the full video, check out the Final Exam Coursehttps://anaesthesia.thinkific.com/courses/finalexamExam StemYou are on the night shift at your tertiary hospital. You are called to resus bay in ED as a 55yo male presents to emergency with severe respiratory distress. You arrive to see a patient with hiflow nasal oxygen, looking unwell, with laboured irregular breathing. Sats 92%. Unable to speak due to respiratory distress. What do you do when you arrive as the doctor leading the resus?Here's a great reference article from the legendary BJA education journalhttps://www.bjaed.org/article/S2058-5349(21)00082-2/fulltext---------Find us atInstagram: https://www.instagram.com/abcsofanaesthesia/Twitter: https://twitter.com/abcsofaWebsite: http://www.anaesthesiacollective.comPodcast: ABCs of AnaesthesiaPrimary Exam Podcast: Anaesthesia Coffee BreakFacebook Page: https://www.facebook.com/ABCsofAnaesthesiaFacebook Private Group: https://www.facebook.com/groups/2082807131964430---------Check out all of our online courses and zoom teaching sessions here!https://anaesthesia.thinkific.com/collectionshttps://www.anaesthesiacollective.com/courses/---------#Anesthesiology #Anesthesia #Anaesthetics #Anaesthetists #Residency #MedicalSchool #FOAMed #Nurse #Medical #Meded ---------Please support me at my patreonhttps://www.patreon.com/ABCsofA---------Any questions please email abcsofanaesthesia@gmail.com---------Disclaimer: The information contained in this video/audio/graphic is for medical practitioner education only. It is not and will not be relevant for the general public.Where applicable patients have given written informed consent to the use of their images in video/photography and aware that it will be published online and visible by medical practitioners and the general public.This contains general information about medical conditions and treatments. The information is not advice and should not be treated as such. The medical information is provided “as is” without any representations or warranties, express or implied. The presenter makes no representations or warranties in relation to the medical information on this video. You must not rely on the information as an alternative to assessing and managing your patient with your treating team and consultant. You should seek your own advice from your medical practitioner in relation to any of the topics discussed in this episode' Medical information can change rapidly, and the author/s make all reasonable attempts to provide accurate information at the time of filming. There is no guarantee that the information will be accurate at the time of viewingThe information provided is within the scope of a specialist anaesthetist (FANZCA) working in Australia.The information presented here does not represent the views of any hospital or ANZCA.These videos are solely for training and education of medical practitioners, and are not an advertisement. They were not sponsored and offer no discounts, gifts or other inducements. This disclaimer was created based on a Contractology template available at http://www.contractology.com.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 18, 2017 Myasthenia gravis is a disorder characterized by proximal weakness, ptosis, and antibody formation against proteins at the neuromuscular junction. Most commonly, the protein targeted by antibodies is the nicotinic acetylcholine receptor. However, research in the last 2 decades has identified a number of other antibody targets, which we have reviewed here in this BrainWaves brief. BrainWaves podcasts and online content are intended for medical education only and should not be used to guide medical decision-making in routine clinical practice. Any cases discussed in this episode are fictional and do not contain any patient health-identifying information. The content in this episode was vetted and approved by Grant T Liu. REFERENCES Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7(4):327-40. PMID 18339348Evoli A, Lancaster E. Paraneoplastic disorders in thymoma patients. J Thorac Oncol 2014;9(9 Suppl 2):S143-7. PMID 25396312Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14(10):1023-36. PMID 26376969Hurst RL, Gooch CL. Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis. Curr Neurol Neurosci Rep 2016;16(7):61. PMID 27170368Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat 2014;224(1):29-35. PMID 23458718 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

In this episode Dr. Daniel Correa talks with jazz musician John Stein about the symptoms he experienced that led to hospitalization and a myasthenia gravis diagnosis. John also shares his recovery and rehab journey after his hospitalization. Next, Dr. Correa sits down with Dr. Carolina Barnett-Tapia, neurologist and associate professor of neurology at the Institute of Health Policy, Management, and Evaluation at the University of Toronto. Dr. Barnett-Tapia explains what myasthenia gravis is and why it may present differently in each person, as well as important considerations for caregivers when someone is newly diagnosed with the condition.  A special thank you to John Stein for permission to feature the title track “No Goodbyes” from his upcoming album release in this week's episode. Available on Spotify and Apple Music.  Additional Resources  https://johnstein.com/   Brain & Life: Physical Activity Helps Manage Myasthenia Gravis   Learn more about myasthenia gravis   Myasthenia Gravis Foundation of America   Other Myasthenia Gravis Brain & Life Podcast Episodes:  Brain & Life Podcast: Ashley Brooks on Advocating for Herself and Others with Myasthenia Gravis   Brain & Life Podcast: Soap Opera Star Suzanne Rogers Brings Awareness to Myasthenia Gravis  We want to hear from you!  Have a question or want to hear a topic featured on the Brain & Life Podcast?  Record a voicemail at 612-928-6206  Email us at BLpodcast@brainandlife.org  Social Media:    Guest: John Stein https://johnstein.com/; Department of Medicine University of Toronto @UofT_DoM (Twitter)  Host: Dr. Daniel Correa @neurodrcorrea 

Show Notes for Episode 28 of “The 2 View” – Live from Vegas, Fungal Meningitis Outbreak, NPs Sue for "Doctor" Title, Guest Chip Lange. When Medical Tourism Goes Wrong CDC. Fungal Meningitis Outbreak Social Media Toolkit. Centers for Disease Control and Prevention. Published July 18, 2023. Accessed July 25, 2023. https://www.cdc.gov/fungal/infections/HAI-fungal-meningitis-toolkit.html Evaluating and Treating Patients for Fungal Meningitis. For both symptomatic and asymptomatic patients: perform lumbar puncture (LP) to evaluate CSF for fungal meningitis* Abnormal LP results Normal initial LP results Counsel patient to monitor for symptoms for 30 days following initial LP Consider scheduling repeat LP two weeks after initial LP Normal repeat LP results. Funguseducationhub.org. Accessed July 25, 2023. https://funguseducationhub.org/wp-content/uploads/2023/06/FM-algorithm_edited.pdf Fungal Meningitis Outbreak Associated with Procedures Performed under Epidural Anesthesia in Matamoros, Mexico. Cdc.gov. Published August 11, 2023. Accessed July 25, 2023. https://www.cdc.gov/hai/outbreaks/meningitis-epidural-anesthesia.html PA Title Change / Nurse Practitioners Sue California to use the Title “Doctor.” Taylor M. Nurse practitioners sue California over restricted use of “doctor.” Beckershospitalreview.com. Published July 18, 2023. Accessed July 25, 2023. https://www.beckershospitalreview.com/hospital-physician-relationships/nurse-practitioners-sue-california-over-restricted-use-of-doctor.html Title Change Rationale. Aapa.org. Accessed July 25, 2023. https://www.aapa.org/title-change/general-faqs/ Malaria Contracted in the US Bendix A, Alexander B. New malaria case in Florida brings national total to 8, the first U.S. acquired cases in 20 years. NBC News. Published July 18, 2023. Accessed July 25, 2023. https://www.nbcnews.com/health/health-news/new-malaria-case-florida-brings-national-total-8-first-us-cases-20-yea-rcna94899 Locally Acquired Malaria Cases Identified in the United States. Health Alert Network (HAN) - 00494. Cdc.gov. Published June 26, 2023. Accessed July 25, 2023. https://emergency.cdc.gov/han/2023/han00494.asp Meat allergy. ACAAI Public Website. Published October 30, 2020. Accessed July 25, 2023. https://acaai.org/allergies/allergic-conditions/food/meat/ Reliability of Fingerstick Glucometers Media H. Picking cherries leads to a case of pseudohyperglycemia. Clinical Advisor. Published December 12, 2016. Accessed July 25, 2023. https://www.clinicaladvisor.com/home/case-files/picking-cherries-leads-to-a-case-of-pseudohyperglycemia/ Olansky L, Kennedy L. Finger-stick Glucose Monitoring. Diabetes Care. Published April 2010. Accessed July 25, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845057/ Special Guest Chip Lange, PA-C, and His Story of Going into Myasthenia Crisis About us. PRACTICAL POCUS. Accessed July 25, 2023. https://www.practicalpocus.com/aboutus.html Cautionary Drugs. Drugs to avoid or use with caution in MG. Myasthenia.org. Accessed July 25, 2023. https://myasthenia.org/Portals/0/Cautionary%20Drugs.pdf Colton, K. Myasthenia Gravis. EM:RAP CorePendium. EM:RAP CorePendium. Updated December 2, 2022. Accessed July 25, 2023. https://www.emrap.org/corependium/chapter/recrDWsB2k1uYPL9U Libsyn, iTunes. Medical professionals. TOTAL EM. Accessed July 25, 2023. https://www.totalem.org/emergency-professionals Something Sweet Woodall AJ, McCrohan CR. Excitatory actions of propofol and ketamine in the snail Lymnaea stagnalis. Comp Biochem Physiol C. ScienceDirect. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology. Volume 127, Issue 3. Pages 297-305. Published December 2000. Accessed July 25, 2023. https://www.sciencedirect.com/science/article/abs/pii/S0742841300001559?via%3Dihub Recurring Sources Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in and see what we have to share!

Myasthenia gravis, or MG, takes a toll on the lives of those living with the condition, but it also affects their loved ones. As Jessica and her husband Jonathan were preparing to welcome their second child into the world, they were not expecting to receive Jessica's MG diagnosis. With this new element added to their lives, they have had to learn how to navigate their evolving family roles, nurture their marriage, and advocate for one another and themselves. In this episode, Jessica and Jonathan share how they have established a new balance in their life together.See omnystudio.com/listener for privacy information.

Myasthenia gravis, or MG, takes a toll on the lives of those living with the condition, but it also affects their loved ones. As Jessica and her husband Jonathan were preparing to welcome their second child into the world, they were not expecting to receive Jessica's MG diagnosis. With this new element added to their lives, they have had to learn how to navigate their evolving family roles, nurture their marriage, and advocate for one another and themselves. In this episode, Jessica and Jonathan share how they have established a new balance in their life together.See omnystudio.com/listener for privacy information.

This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction. Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient's comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical trial data on these therapies were presented at the American Academy of Neurology Annual Meeting (AAN 2023) held in Boston, MA. This CME program, hosted by Vera Bril, MD, of the University Hospital Network in Toronto, Canada, provides an overview of the latest clinical research presented at AAN 2023 focused on myasthenia gravis. Supported by educational grants from argenx US, Inc. and UCB Inc. For complete activity information and to obtain CME credit, please, go to https://checkrare.com/learning/p-myasthenia-gravis-research-highlights-aan-2023/

Myasthenia gravis, or MG, affects people of all ages and races and is most commonly diagnosed later in life. However, for Anaya, her MG symptoms began when she was just 12 years old. Anaya went from being an active young athlete to struggling with immobility and school attendance. As a young black girl, Anaya's age and race demographics complicated her MG diagnosis journey. However, by learning to advocate for herself and acknowledging her physical limitations, Anaya has been able to reframe her life with MG. She is now an ambitious college graduate and champion for other young people learning to live with this rare condition.See omnystudio.com/listener for privacy information.

Sindhu Ramchandren, MD, Global Clinical Leader at Janssen Pharmaceuticals, explains the pathophysiology of myasthenia gravis and the need for more targeted therapies.Myasthenia gravis is an autoimmune, neuromuscular disorder characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control the eyes, eyelids, facial expressions, chewing, talking, and swallowing. The presence of antibodies against acetylcholine receptors in the neuromuscular junction usually causes the condition.As Dr. Ramchandren explains, myasthenia gravis is an autoimmune disease in which the person's own immune system attacks ACh-receptors on the neuromuscular junction. The current standard of care for myasthenia gravis is to suppress the immune system, usually with broad-acting immunosuppressants. Dr. Ramchandren believes a more targeted approach would be of greater benefit to patients. Janssen is currently developing nipocalimab, a monoclonal antibody that binds to neonatal Fc receptors (FcRn). FcRn is a protein that naturally drives IgG recycling in the body. By blocking FcRn, nipocalimab reduces the levels of IgG autoantibodies while preserving the rest of the immune system.Recently, in a phase 2 clinical trial, patients with myasthenia gravis were given nipocalimab. As a result, a dose-dependent rapid effect was observed on various disease biomarkers, including reduced titers of autoantibodies. Currently, A phase 3 clinical trial is underway (NCT04951622). To learn more about this and other autoimmune disorders, go to checkrare.com/diseases/autoimmune-auto-inflammatory-disorders/

This week Dr. Daniel Correa speaks with chronic illness blogger and advocate Ashley Brooks. Ashley talks about the symptoms she experienced that led to her myasthenia gravis (MG) diagnosis, the various treatments she has received, and how her diagnosis inspired her to start online advocacy and outreach to raise awareness of this neurologic condition. Following her interview, Dr. Correa sits down with Dr. Gordon Smith, professor and chair of neurology at Virginia Commonwealth University. Dr. Smith explains how MG affects the immune system and the difference between crisis treatments and more long-term treatments for someone with MG.  Episode content produced by Brain & Life and the American Academy of Neurology without involvement from the ad sponsor.  Additional Resources  https://ashleysanatomy.com/   Learn more about myasthenia gravis  Brain & Life: How Clinical Trials Can Empower Myasthenia Gravis Patients and Advance Treatment Research   Brain & Life: How to Manage Swallowing Disorders   Brain & Life: Shining a Light on Myasthenia Gravis: How a Blogger Raises Visibility  Brain & Life: When Is a Thymectomy Appropriate for Treating Myasthenia Gravis?  We want to hear from you!  Have a question or want to hear a topic featured on the Brain & Life Podcast?  Record a voicemail at 612-928-6206  Email us at BLpodcast@brainandlife.org  Social Media:    Guest: Ashley Brooks @_AshleysAnatomy (Instagram); Dr. Gordon Smith @GordonSmithMD  Hosts: Dr. Daniel Correa @neurodrcorrea 

With a rare neuromuscular condition like myasthenia gravis, or MG, everyone's experience with the disease is unique and often filled with struggles and sacrifices. That's why argenx has partnered with iHeartRadio to bring you “Untold Stories: Life with Myasthenia Gravis.” In each episode, host Martine Hackett will explore the lessons learned and obstacles overcome by real people living with MG and share their empowering perspectives. Listen every other week to find strength and inspiration in these stories from members of the MG community.See omnystudio.com/listener for privacy information.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 18, 2017 Our 9th episode features an evolving case discussion about a patient with eye movement difficulties. Dr. Ali Hamedani navigates us through the orbit, brainstem, and midbrain as we discern the structural and physiological problems that can impede extra-ocular movements. BrainWaves podcasts and online content are intended for medical education only and should not be used to guide medical decision-making in routine clinical practice. Any cases discussed in this episode are fictional and do not contain any patient health-identifying information. This episode was vetted and approved by Grant Liu. REFERENCES Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008;358(24):2594-605. PMID 18550875Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43(10):1911-7. PMID 8413947Cornblath WT. Diplopia due to ocular motor cranial neuropathies. Continuum (Minneap Minn). 2014 Aug;20(4 Neuro-ophthalmology):966-80. PMID 25099103Dallow RL, Pratt SG. Approach to orbital disorders and frequency of disease occurrence. In: Albert DM, Jakobiec FA, editors. The Principles and Practices of Ophthalmology: Clinical Practice. v3. WB Saunders Co.: Philadelphia, 1994.Liu GT, Volpe NJ, Galetta SL. Neuro-Ophthalmology: Diagnosis and Management. 2nd ed. Elsevier, 2010.Sanders DB, Guptill JT. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum (Minneap Minn) 2014;20(5 Peripheral Nervous System Disorders):1413-25. PMID 25299290 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date. 

Go online to PeerView.com/PAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Conventional treatments (eg, corticosteroids, azathioprine, cyclosporine) are broadly immunosuppressive, do not target pathogenic IgG autoantibodies, often provide insufficient symptom relief, and are associated with significant side effects, leaving patients with substantial disease and treatment burden. Fortunately, advances in the understanding of MG pathogenesis are leading to the development of new therapeutics such as Fc receptor modulators and complement inhibitors that more selectively address the underlying disease process. Test your knowledge on this rare disease through this question-based activity. Upon completion of this activity, participants should be better able to: Recognize the range of signs and symptoms associated with myasthenia gravis (MG) to expedite an accurate diagnosis; Identify patients whose MG is not adequately controlled on their current treatment regimen; and Explain why and how to implement use of Myasthenia Gravis Activities of Daily Life (MG-ADL) in clinical care

Go online to PeerView.com/PAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Conventional treatments (eg, corticosteroids, azathioprine, cyclosporine) are broadly immunosuppressive, do not target pathogenic IgG autoantibodies, often provide insufficient symptom relief, and are associated with significant side effects, leaving patients with substantial disease and treatment burden. Fortunately, advances in the understanding of MG pathogenesis are leading to the development of new therapeutics such as Fc receptor modulators and complement inhibitors that more selectively address the underlying disease process. Test your knowledge on this rare disease through this question-based activity. Upon completion of this activity, participants should be better able to: Recognize the range of signs and symptoms associated with myasthenia gravis (MG) to expedite an accurate diagnosis; Identify patients whose MG is not adequately controlled on their current treatment regimen; and Explain why and how to implement use of Myasthenia Gravis Activities of Daily Life (MG-ADL) in clinical care

Carolyn McMakin, MA, DC Kim Pittis, LCSP, (PHYS), MT 1:27 Circle practicum 7:01 Treating seven Ehlers-Danlos at once 19:00 Increasing secretions and vitality in facia and adipose? 24:21 Take out the bad stuff, put in the good stuff 27:08 Phantom limb pain 35:25 Bulging disc facet blocks 44:09 Thalamic pain fused discs 48:23 Plication surgery 50:37 49/97 with Kinesio tape 52:36 81 in the vagus 56:02 Myasthenia gravis 56:20 FSM is good for humility 58:18 FSM is a language

Episode 30. En kort oversikt over medisinsk behandling av Myasthenia gravis. I denne episoden får du en gjennomgang av acetylcholinesterase hemmere, steroider, ulike cellegifttyper og litt om andre behandlinger. Behandlingsprinsippene er viktig å kjenne til også for pasientene. Vi snakker ikke om de nye medisinene (uten godkjenning) i denne episoden, de nevnes kun kort på slutten av episoden. I studio er Karoline Haslum og Jeanette Koht. De intervjuer Angelina Maniaol, overlege på Oslo universitetssykehus. Redaksjon: Karoline Haslum (lege i spesialisering), Lise Elveseter (lege i spesialisering) og Jeanette Koht (nevrolog, ph.d). Jingle: Christoffer E. Hørbo og Are Brean. Logo: Tilde Rasmussen. Produsert av Oslo universitetssykehus, Nevrologisk avdeling. Følg oss på Facebook og Instagram!  

In this episode, Dr. Daniel Correa talks with actress, Suzanne Rogers. Suzanne shares how her myasthenia gravis diagnosis has affected her acting career and her efforts to bring awareness to the condition through featuring it on Days of Our Lives. Next, Dr. Correa speaks with Dr. Nicholas Silvestri, a neurologist and nerve specialist at the University of Buffalo and Buffalo General Medical Center. Dr. Silvestri discusses ways to manage myasthenia gravis and treatment options for those diagnosed with the condition.  Additional Resources:    https://www.brainandlife.org/disorders-a-z/disorders/myasthenia-gravis   https://www.brainandlife.org/editorials/a-work-in-progress    Social Media:    Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Audrey Nath @AudreyNathMDPhD

Jasmine worked in the disability field for over a decade before becoming disabled herself with myasthenia gravis. Myasthenia gravis is a chronic autoimmune, neuromuscular disease that causes weakness in the skeletal muscles that worsens after periods of activity and improves after periods of rest. Jasmine walks the fellas through her list of treatments (including needing to pump her own lungs to breathe easier) and how her illness has put into perspective how important her work is. Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

Jasmine worked in the disability field for over a decade before becoming disabled herself with myasthenia gravis. Myasthenia gravis is a chronic autoimmune, neuromuscular disease that causes weakness in the skeletal muscles that worsens after periods of activity and improves after periods of rest. Jasmine walks the fellas through her list of treatments (including needing to pump her own lungs to breathe easier) and how her illness has put into perspective how important her work is. Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

Myasthenia gravis and Lambert Eaton syndrome are two neuromuscular disorders that are commonly tested but can be easily confused due to their similar presentations. In this episode, medical student Divya Patel reviews the separate pathophysiology and presentation of each disease so that you can tell the difference on any exam!

James Howard Jr., MD, Distinguished Professor of Neuromuscular Disease and Professor of Neurology and Medicine at UNC School of Medicine, reviews the treatment landscape for myasthenia gravis. Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control the eyes, eyelids, facial expressions, chewing, talking, and swallowing. The condition is usually due to the presence of antibodies against acetylcholine receptors in the neuromuscular junction.As Dr. Howard explains, due to the variety of ways this rare disease can present, treatment of myasthenia gravis is individualized to each patient based on their specific symptoms and unique comorbidities. In addition, the financial situation of each patient is taken into account.Acetylcholinesterase inhibitors are often used as bridge therapies. Corticosteroids are also common bridge therapies in younger patients, while steroid sparing agents are more common in older patients or in patients with contraindications to steroids. In patients under the age of 60 with generalized disease and who are anti-acetylcholine receptor (AChR) antibody positive, the removal of the thymus gland is common. Dr. Howard goes on to discuss approved treatments for myasthenia gravis. In 2017, eculizumab, a complement inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. More recently, in December 2021, the FDA approved efgartigimod alfa, an FcRn inhibitor, for the treatment of this same patient population. This approval was based on positive results from the global phase 3 ADAPT trial, which were published in the July 2021 issue of The Lancet Neurology. While Dr. Howard stresses the need for individualized treatment for all myasthenia gravis patients, he is optimistic about the future of FcRn inhibitors in the treatment of myasthenia gravis.

Mother:  We revisit the murderer from Episode 1 and how his conviction in that case made authorities look into his wife's death, years previously.Cameron:Boris tribute page when?....This week we cover: Murder, Financial Abuse, Blue Beard, 999 callsContact us:Email: murdermeonmondaypodcast@gmail.comTwitter: https://twitter.com/MMonMondayInstagram: https://www.instagram.com/murdermeonmondaypodcast/Sources:https://www.judiciary.uk/wp-content/uploads/2022/02/R-v-Stewart-Sentencing-Remarks.pdfhttps://www.itv.com/news/anglia/2022-02-01/the-999-call-made-by-husband-on-trial-for-wifes-murderhttps://www.itv.com/news/anglia/2022-02-09/the-master-manipulator-who-thought-he-had-got-away-with-murder-twicehttps://www.dailymail.co.uk/news/article-10460401/Husband-convicted-murdering-author-Helen-Bailey-paid-28-000-life-insurance-policy.htmlhttps://www.dailymail.co.uk/news/article-10414325/Man-killed-childrens-author-Helen-Bailey-trial-wifes-murder.htmlhttps://www.itv.com/news/anglia/2022-02-01/the-999-call-made-by-husband-on-trial-for-wifes-murderhttps://en.wikipedia.org/wiki/Myasthenia_gravishttps://twitter.com/JonIronmonger/status/1488916552120422404?s=20&t=blvPuhS2kTVyV5gCgaMOfwTheme Tune is published under license from:   Tribe of Noise – Awkward Mystery https://prosearch.tribeofnoise.com/artists/show/29267/32277 

Here are the links for everything discussed in Episode 73. Times are also below so feel free to skip around and get to the drugs that interest you.  (1:17) New EUA issued for molnupiravir for treatment of COVID-19 (6:10) Apretude approved for pre-exposure prophylaxis/PrEP (9:33) New treatment approved for Myasthenia Gravis named Vyvgart (12:18) Tezspire approved for severe asthma CDC website for COVID information - get boosted!Connect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

Autoimmune diseases including Rheumatoid Arthritis, Sarcoidosis, Lupus erythematous, Irritable bowel disease, Multiple sclerosis, Type I diabetes, Guillain-barre Syndrome, Psoriasis,Graves disease, Hashimoto's thyroiditis, Myasthenia gravis, and Vacuitis, effect many millions of people all over the world. They destroy lives and while they may not kill you they make make you wish you were dead. Is there and effective and safe natural answer? Is there a cure? We discuss this and offer the best way to treat these previously incurable diseases.

Autoimmune diseases including Rheumatoid Arthritis, Sarcoidosis, Lupus erythematous, Irritable bowel disease, Multiple sclerosis, Type I diabetes, Guillain-barre Syndrome, Psoriasis,Graves disease, Hashimoto's thyroiditis, Myasthenia gravis, and Vacuitis, effect many millions of people all over the world. They destroy lives and while they may not kill you they make make you wish you were dead. Is there and effective and safe natural answer? Is there a cure? We discuss this and offer the best way to treat these previously incurable diseases.

In this episode I cover Lambert-Eaton myasthenic syndrome.If you want to follow along with written notes on Lambert-Eaton myasthenic syndrome go to https://zerotofinals.com/medicine/neurology/lamberteaton/ or the neurology section in the Zero to Finals medicine book.This episode covers pathophysiology, presentation, diagnosis and management of Lambert-Eaton myasthenic syndrome.The audio in the episode was expertly edited by Harry Watchman.